We're conducting an influenza vaccine marketing project, but the regulations prevent us from using certain new technologies that you referred to, such as those related to messenger RNA vaccines. At any event, they complicate the use of those vaccines.
In addition, a bacterium from Asia is currently posing a threat, and we need to develop a vaccine for it, but no one wants to market it because there isn't really any volume. It would cost $1.2 million just to get agency authorization to market production of 25,000 doses on an emergency basis. We agree that it's very difficult to come up with that kind of money, but it would be extremely important to have that vaccine bank in the event a crisis arises in some of our facilities.